logo
  • Home
  • Solution
  • Impact
  • Science
    • Publications
  • About
    • Team and Board
  • News and Events
    • All News
    • All Events
    • All Press Releases
  • Contact

Month: September 2022

Excellent results from phase I study shows that the BioC gel is safe and well tolerated.

The first part of the phase I study has now been unblinded. The result shows that BioC gel is both safe and well tolerated. There were no adverse events reported and no systemic effect detected.


by Helene Hartman

Recent Posts

  • First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25
  • Xinnate Completes Oversubscribed Share Issue of SEK 38,5m
  • Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa
  • EB 2026: 20-22 Jan 2026
  • EB Awareness week: 25-31 Oct 2025

Archives

  • December 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • January 2025
  • December 2024
  • September 2024
  • May 2024
  • March 2024
  • February 2024
  • March 2023
  • October 2022
  • September 2022
  • July 2022
  • March 2022
  • August 2021
  • October 2020
  • January 2020
© 2026 Xinnate. All rights reserved